NCT ID | Study Title | Action |
---|---|---|
NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | View |
NCT01506973 | A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer | View |
NCT01134276 | Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers | View |
NCT01652976 | Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma | View |
NCT05110573 | Single-centre Propensity Score-matched Comparison of Laparoscopic Versus Open Pancreatoduodenectomy | View |
NCT05095831 | EUS Shear Wave for Solid Pancreatic Lesions. | View |
NCT00674973 | A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer | View |
NCT03401827 | The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer | View |
NCT01445327 | Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers | View |
NCT02550327 | Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer | View |
NCT00426127 | Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer | View |
NCT00024427 | Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer | View |
NCT00059826 | Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer | View |
NCT03415126 | A Study of ASN007 in Patients With Advanced Solid Tumors | View |
NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies | View |
NCT04386057 | LY3214996 +/- HCQ in Pancreatic Cancer | View |
NCT02121626 | The FOCCUS Study: ȯocusing on Cancers Chemotherapys' Untreated Symptoms" | View |
NCT02528526 | Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm | View |
NCT00253526 | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer | View |
NCT01523457 | Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer | View |
NCT00709826 | APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer | View |
NCT00899626 | Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients | View |
NCT05472857 | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | View |
NCT02671357 | Enhanced Recovery After Minimally Invasive Pancreaticoduodenectomy | View |
NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | View |
National Pancreatic Cancer Foundation provides access to clinical research studies. This information is provided by clinicaltrials.gov and is maintained by the National Library of Medicine (NLM). Neither NPCF nor the US government review or approve the safety and science of the studies on this website. Read the disclaimer for details.
NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.
The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.
Copyright © 2024 – National Pancreatic Cancer Foundation | All Rights Reserved